Frequency Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 10, 2022 at 01:47 am IST
Share
Frequency Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 21.29 million compared to USD 17.66 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to USD 0.52 a year ago.
For the six months, net loss was USD 44.67 million compared to USD 38.03 million a year ago. Basic loss per share from continuing operations was USD 1.28 compared to USD 1.11 a year ago.
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Companyâs first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.